ChemPartner PharmaTech Co (300149.SZ) Stock Price
ChemPartner PharmaTech Co Price
Over the last 18 years ChemPartner PharmaTech Co grew revenue by 17.2% annually, reaching 1.13 B CNY. Earnings per share have grown at 0.6% per year over the last 18 years. For ChemPartner PharmaTech Co, the net margin of 1.2% is up versus -23.8% a few years ago. At today's price the dividend yield works out to roughly 0.74%. The dividend has grown at 12.6% per year over the past 10 years.
ChemPartner PharmaTech Co stock price
ChemPartner PharmaTech Co business model & stock analysis
Frequently asked questions about ChemPartner PharmaTech Co
5 analysts currently rate the ChemPartner PharmaTech Co stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the ChemPartner PharmaTech Co share trades at 1.26 EUR (9.47 CNY).
The revenue cannot currently be calculated for ChemPartner PharmaTech Co.
The profit cannot currently be calculated for ChemPartner PharmaTech Co.
The P/E ratio cannot be calculated for ChemPartner PharmaTech Co at the moment.
The P/S cannot be calculated for ChemPartner PharmaTech Co currently.
The Eulerpool Quality Score for ChemPartner PharmaTech Co is 3/10.
The ISIN of ChemPartner PharmaTech Co is CNE100000Y27. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of ChemPartner PharmaTech Co is 300149.SZ. The ticker symbol is used to trade ChemPartner PharmaTech Co shares on the stock exchange.
ChemPartner PharmaTech Co stock
ChemPartner PharmaTech Co Peer Group
ChemPartner PharmaTech Co FIGI
All fundamentals and in-depth analysis of ChemPartner PharmaTech Co
Our stock analysis for ChemPartner PharmaTech Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ChemPartner PharmaTech Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.